Skip to main content

BioCommunique Article

Bringing you the latest financial and strategic news from top leaders in life science over the past two weeks.

BI Acquires ViraTherapeutics, Epic Sciences Raises $52M, CRISPR Therapeutics and Vertex Sponsor First CRISPR Trial

  • 2018-09-13T05:27:00.000+0000
  • California
  • Author: Lauren Panetta

09/13/18 – Fierce Biotech
AbbVie builds case for potential blockbuster risankizumab

09/13/18 – Bird Rock Bio
Bird Rock Bio Completes Clinical Trial of Nimacimab in Patients with Fatty Liver Disease

09/13/18 – GEN
Boehringer Ingelheim Acquires Viral-Based Cancer Immunotherapy Developer ViraTherapeutics

09/13/18 – Fate Therapeutics
Fate Therapeutics Enters into Exclusive License Agreement with Gladstone Institutes for CRISPR-based Cellular Reprogramming

09/13/18 – Endpoints News
Genentech team does some cutting-edge work on a new class of antibiotics — here’s why that’s important

09/12/18 – FibroGen
FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis

09/12/18 – The San Diego Union-Tribune
Cancer test maker Epic Sciences raises $52 million

09/12/18 – Fierce Biotech
BMS plans for phase 3 after psoriasis drug shows skin clearance

09/11/18 – BioSci Capital Partners
Conatus: Elucidating The Upcoming Binary Catalyst For Emricasan

09/11/18 – Endpoints News
GSK-backed scientific team at UCSF says they found the immortality switch in cancer cells — and know how to turn it off

09/07/18 – GEN
Thermo Fisher Acquiring BD's Advanced Bioprocessing Business

09/07/18 – Fierce Biotech
Pfizer taps Cytoo for help identifying DMD targets

09/06/18 – Genome Web
Evotec, Celgene Partner on Targeted Protein Degradation for Drug Discovery

09/05/18 – Genome Web
Quidel Amends Credit Agreement for $175M

09/05/18 – The San Diego Union-Tribune
UC San Diego partners in $65 million project to speed drug development

09/05/18 – Fierce Biotech
Startup Gossamer Bio hires Bristol-Myers Squibb executive as CSO

09/05/18 – Fierce Biotech
Sean Harper and Beth Seidenberg unite to run $320M VC fund

08/31/18 – Fierce Biotech
CRISPR, Vertex start first company-backed human gene trial